CD8A and pancreatic neoplasm: Small-molecule CCR2 inhibitors (CCR2i) improve gemcitabine’s efficacy and increase CD8 infiltration in pancreatic cancer [103], and increase the overall survival in mice with mCRC liver tumors [104].